June 2, 2025
Source: drugdu
76
On May 29, Mywell Biopharmaceuticals (688062) announced that the marketing application for Agrastim α for injection submitted by its wholly-owned subsidiary Jiangsu Taikang Biotechnology Co., Ltd. was approved by the National Medical Products Administration.
The drug is suitable for adult patients with non-myeloid malignancies who are receiving myelosuppressive anticancer drugs that are prone to cause febrile neutropenia. The drug can be used to reduce the incidence of infections manifested by febrile neutropenia.The marketed product is also the first domestically marketed G-CSF drug developed using long-acting albumin fusion technology.
In the first quarter of 2025, Mabwell Biopharmaceuticals achieved revenue of 44.79 million yuan and a net profit attributable to shareholders of the parent company of -292 million yuan.
https://finance.eastmoney.com/a/202505293418060776.html
By editoryour submission has already been received.
OK
Please enter a valid Email address!
Submit
The most relevant industry news & insight will be sent to you every two weeks.